2016 ABFO National Conference Agenda - Proposed
TUESDAY, MAY 24

6:00 to 8:00 pm
Welcome - Cocktail Reception
WEDNESDAY, MAY 25
7:00 am Breakfast
8:50 am
Welcome | Day 1 Introductions and Announcements
2016 San Diego Conference Co-Chairs: Vanessa Jacoby, PharmAkea Therapeutics, Inc.
Dan Chevallard, Regulus Therapeutics, Inc.
 
9:00 am
KEYNOTE SPEAKER: Shankar Vedantam, Journalist, NPR Social Science Correspondent, Author: The Hidden Brain
Shankar Vedantam, author of The Hidden Brain, will speak about how unconscious factors in the mind shape the way we think about innovation, communication and risk.
10:15 am Break/Transition - 15 Minutes
10:30 am
GUEST SPEAKER:" The Importance of Early Stage Collaboration" Darren Snellgrove, Chief Financial Officer, Johnson & Johnson Innovation/Panel Dicussion to follow
Darren will be presenting on “The Importance of early stage collaboration”. During his presentation Darren will take us through the journey of J&J Innovation, how it came to be, the challenges he faced as CFO, how he thinks about value creation, and why he is convinced that early stage collaboration is critical to the long-term success of J&J.
 
11:00 am
PANEL DISCUSSION: Q&A with Darren Snellgrove, "Pharma's Role in Innovative Biotech Financing",
This panel will discuss the role of pharma in biotech innovation and financing. Pharma and biotech can synergistically generate asset pipelines by leveraging pharma financing and expertise with biotech efficiency and innovation.
 

PANELISTS:
Ed Kenkel, Finance Director, Johnson & Johnson California Innovation Center
Robert Williamson, Chief Executive Officer, PharmAkea Therapeutics, Inc.
Sandy Madigan, Chief Executive Officer, Ankasa Regenerative Therapeutics
Jennifer Lew, Senior Vice President of Finance, Aduro Biotech

11:45 am Lunch: 11:45 am - 12:55 pm
12:55 pm
PANEL DISCUSSION: "A CEO's View of Managing/Interacting with Your Board of Directors and Audit Committee"
This panel brings together a seasoned group of industry veterans to discuss the current life sciences challenges presented and the opportunities and the role of the CFO in supporting the company and Board of Directors. Also, these CEOs will discuss their perspectives on the role of finance in an organization and how the CFO can go from being a number cruncher to a trusted advisor to the CEO and Board.
 
MODERATOR: Cheston Larson, Partner, Latham & Watkins
PANELISTS:  
Laura Brege, Managing Director, Cervantes Life Sciences Partners, LLC
Gerry Proehl, President & Chief Executive Officer, Dermata Therapeutics, LLC

Ted Schroeder, Chief Executive Officer & Director, Zavante Therapeutics, Inc.

1:55 pm Break/Transition - 5 Minutes
2:00 pm
Roundtable Discussions
 
Early Financing MODERATOR - Kyri Van Hoose, Partner, van den Boom & Associates

This moderated roundtable discussion group for early-stage companies seeking financing will focus on exploring opportunities that have been created by the promise of returns for investors, and the money sources that have been attracted to our sector. Topics will include: what's getting financed privately, prospects for continued support in public and private markets, alternatives for getting public and how the finance team should prepare to ensure their companies have continued access to needed capital.

Pre-IPO MODERATOR - Matthew Fust, Life Sciences Company Advisor, Board Member, Atara Biotherapeutics, Dermira, MacroGenics

This moderated roundtable discussion will cover issues critical to setting your company up for a successful IPO.  Topics include reaching out to potential strategic partners, leveraging your network of investment bankers and money sources, building your management team, ensuring that your Board and investors are aligned with common goals, dealing with analysts and market watchers, and setting performance targets for the company and the team.

Public Less than Three Years MODERATOR - Harry Trout III, Sr. Director of Finance, ENANTA Pharmaceuticals, Inc.

This moderated roundtable discussion focuses on the issues faced by companies who’ve just gone public/or who have been public less than three years. Topics will include: optimal resource and staffing headcount and complement, ERP challenges, stock-based compensation programs, investor relations, best practices for interacting with the audit committee and board, and SOX 404 considerations, amongst others.

Public Three Years or More MODERATOR - Brandi Roberts, Chief Financial Officer, Mast Therapeutics, Inc.

This moderated roundtable discussion will focus on issues commonly faced by mature life science companies that have been public for three years or more and have or are about to launch commercial products. Topics will include product launch challenges, considerations and best practices, international expansion issues, distribution models, FCPA, tax planning strategies and ERP-related issues, amongst others.

3:15 pm Break/Transition - 10 minutes
3:25 pm
PANEL DISCUSSION: "Recent Trends in Mergers & Acquisitions"
Join seasoned life sciences executives for a dynamic discussion focused on recent mergers & acquisitions trends and their straight from the trenches experiences with M&A deals. Our panel will provide insights on both private and public M&A transactions, with an emphasis on how best to prepare for your own M&A deal and the key “do’s and don’ts’” for these transformative transactions.
 
MODERATOR: Cheston Larson, Partner, Latham & Watkins
PANELISTS:
Trisha Millican, Chief Financial Officer, Metacrine, Inc.
Richard A. Heyman, PhD, Executive Chairman, Metacrine, Inc.
Christian Waage, Managing Director, Receptos Inc.
Bradley Wolff, Head of West Coast Life Sciences, Managing Director, Investment Banking, Bank of American Merrill Lynch
4:25 pm Break/Transition - 10 minutes
4:35 pm
GUEST SPEAKER: Andrew S. Fastow, Former Chief Financial Officer, Enron
Andrew will share his experiences in finance and provide observations about how the ambiguity and complexity of laws and regulations breeds opportunity for problematic decisions. He will also discuss what questions corporate directors, management, attorneys, and accountants should ask in order to ensure that their companies not only follow the rules, but uphold the principles behind them.
5:30 pm
Brief Announcements
5:35 pm
Regional Coordinators' Meeting
6:30 pm
Wednesday Night Social Event - Petco Park - The Loft@Toyota Terrace  Pick up your tickets before you go.
THURSDAY, MAY 26
7:00 am Breakfast
8:50 am
Welcome | Day 2 Announcements
9:00 am
GUEST SPEAKER: Joe Quinlan, Managing Director & Chief Market Strategist, U.S. Trust, Bank of America, Private Wealth Management,  
"Global Economic Insights and Outlook"
Identifying  the  main  drivers  of  long-term  change  is  key  to  investment  success  in  the  21st century. We believe we are at the beginning of a secular growth phase for the U.S. economy driven largely by the rebalancing of global growth from the developed to the developing world. Joe will discuss the  long-term drivers, the macro forces and investment themes at play across industries that are taking us into the next growth cycle.
10:00 am Break/Transition - 15 minutes
10:15 am
BREAKOUT SESSIONS - Select One
A. A & A Update - Presented by Ernst & Young
Update on the latest accounting developments that are expected to impact bioscience companies with a particular focus on the new revenue recognition standard. EY will share their insights on how the new standard is being interpreted, what bioscience companies should be focused on, and how the various regulatory bodies expect to see the standard implemented.

  PRESENTERS: John Clift, Partner, Ernst & Young LLP
Casey Hayes, Partner, Ernst & Young LLP
B. "Acting for Executives"
Terrified of speaking in public? Intimidated by speaking in front of your peers? Looking to hone your skills as a public presence? Whether building team relationships or presenting business plans to potential investors, the most successful business people are confident public speakers. Techniques used by actors to overcome stage fright and create exciting performances can be used in the workplace to communicate effectively, build stronger teams and increase confidence and leadership skills. This course will help you with relaxation, concentration, public speaking and team building exercises used in the theater to create more confident business professionals.
  PRESENTER: Professor Rebecca Johannsen - UC, San Diego

C. "Best Practices for Managing Global Clinical Finance"
Are your corporate finance interests and clinical trial goals aligned? This panel of experts from Ernst & Young, Mast Therapeutics, Mirati Therapeutics, and Medidata Solutions will discuss best practices for managing global clinical finance across your R&D portfolio. They’ll address common pitfalls when it comes to managing the site payment process on global trials, managing accruals, forecasting and transparency reporting, outsourcing clinical finance operations, and selecting technology.

  PRESENTERS: April Mulroney, Managing Director, Payments, Medidata Solutions
Brandi Roberts, Senior Vice President, Chief Financial Officer, Mast Therapeutics, Inc.
Vickie Reed, Senior Director and Controller Mirati Therapeutics, Inc.
Alex Cotopoulis, Americas VAT Practice, Ernst & Young LLP
Marcus Thornton, Glorbal Lead, Payments, Medidata Solutions

D. Business Structure and Tax Strategies for Start-ups
A focused look at how to structure life science start-ups in the most efficient and tax effective manner. What are the pros and cons of the various structures that are currently popular and what structure may be best for your company.

    PRESENTERS: Matthew T. Bush, Partner, Latham & Watkins LLP
Nir Shtolzberg, Southern California R&D Credit Services Leader, Ernst & Young LLP
Todd Carper, Principal, Ernst & Young LLP
11:40 am Lunch - 11:40 am - 12:50 pm
12:50 pm
BREAKOUT SESSIONS - Select One
A. A & A Update - Presented by Ernst & Young
Update on the latest accounting developments that are expected to impact bioscience companies with a particular focus on the new revenue recognition standard. EY will share their insights on how the new standard is being interpreted, what bioscience companies should be focused on, and how the various regulatory bodies expect to see the standard implemented.
  PRESENTERS: John Clift, Partner, Ernst & Young LLP
Casey Hayes, Partner, Ernst & Young LLP
B. "Acting for Executives"
Terrified of speaking in public? Intimidated by speaking in front of your peers? Looking to hone your skills as a public presence? Whether building team relationships or presenting business plans to potential investors, the most successful business people are confident public speakers. Techniques used by actors to overcome stage fright and create exciting performances can be used in the workplace to communicate effectively, build stronger teams and increase confidence and leadership skills. This course will help you with relaxation, concentration, public speaking and team building exercises used in the theater to create more confident business professionals.
  PRESENTER: Professor Rebecca Johannsen - UC, San Diego
C. "Best Practices for Managing Global Clinical Finance"
Are your corporate finance interests and clinical trial goals aligned? This panel of experts from Ernst & Young, Mast Therapeutics, Mirati Therapeutics, and Medidata Solutions will discuss best practices for managing global clinical finance across your R&D portfolio. They’ll address common pitfalls when it comes to managing the site payment process on global trials, managing accruals, forecasting and transparency reporting, outsourcing clinical finance operations, and selecting technology.
  PRESENTERS: April Mulroney, Managing Director, Payments, Medidata Solutions
Brandi Roberts, Senior Vice President, Chief Financial Officer, Mast Therapeutics, Inc.
Vickie Reed, Senior Director and Controller, Mirati Therapeutics, Inc.
Alex Cotopoulis, Americas VAT Practice, Ernst & Young LLP
Marcus Thornton, Global Lead, Payments, Medidata Solutions

D. Business Structure and Tax Strategies for Start-ups
A focused look at how to structure life science start-ups in the most efficient and tax effective manner. What are the pros and cons of the various structures that are currently popular and what structure may be best for your company.

    PRESENTERS: Michael Sullivan, Partner, Latham & Watkins LLP
Nir Shtolzberg, Southern California R&D Credit Services Leader, Ernst & Young LLP
Todd Carper, Principal, Ernst & Young LLP
2:15 pm Break/Transition - 15 minutes
2:30 pm

KEYNOTE SPEAKER: Jim Thomas, "Negotiation"
Bioscience financial officers are negotiators. Successfully providing expert financial management services means navigating complex waters of budgeting, reporting, contracting, controls, banking, funding, investing, cash flow, regulatory compliance, risk, insurance, benefits, inventory management, and much, much more. Finding positive outcomes in this environment requires nothing less than best-in-class negotiating skills.

Jim will explore how better negotiating can help transform financial management from a function into a set of values and processes that can permeate the entire organization and improve financial performance. He’ll describe a full range of best negotiating practices and countermeasures to help parties find outcomes that work.

4:00 pm Break/Transition
4:15 pm
GUEST SPEAKER: Emily Burke, PhD., Biotech Primer - "Immunotherapies 101"
  A review of the basics of the immune system, and then apply that knowledge to understanding a whole class of established and emerging therapeutics.
  • Monoclonal antibody (mAb) therapies are still hot after almost 20 years on the market - why? How do they work?
  • Recent innovations have made mAbs even more effective - learn what antibody-drug conjugates and bispecific antibodies are, and why drug companies are racing to develop them.
  • PCSK9 inhibitors (a form of mAb) - one of the most talked-about FDA approvals last year - show that mAbs are relevant not just for cancer and autoimmune disorders, but also for cardiology.
  • Finally, learn how immunology is on the forefront of oncology treatments in the form of checkpoint inhibitors, CART, even a viral-based cancer vaccines, all designed to boost patient's own immune system in recognizing and fighting cancer.
5:15 pm
Brief Announcements
5:30 pm
Depart For Thursday Night Mystery Event
FRIDAY, MAY 27
7:00 am Breakfast
8:50 am
Welcome | Day 3 Introductions
2017 Philadelphia Conference Chair: Lou Arcudi, Chief Financial Officer, Idera Pharmaceuticals, Inc.
9:00 am
WASHINGTON and STATE ADVOCACY PANEL
Will Waddill, Chief Financial Officer, Calithera Biosciences, Inc.
The Washington update panel will provide an inside look at the issues facing the life science industry and how legislators in Washington DC and state capitals have an influence on how we run our companies. The Jobs Act, and Affordable Care Act are just two examples of the major pieces of legislation that were influenced by our panel and impacted us all. In fact, the IPO window many of us just took advantage of was propelled by the initiatives in the jobs act. The $5 billion R&D grants from the Affordable Care Act provided life science companies a needed shot in the arm as we struggled to raise capital in the depths of the recession and was the only portion of the bill where Washington actually paid out funding to assist an industry. SEC reporting, IRS tax rules, and the FDA approval process are all in the hands of our legislators and are on the forefront of advocacy issues our panel will discuss.
   

MODERATOR: Will Waddill, Senior Vice President, Chief Financial Officer, Calithera Biosciences, Inc.
PANELISTS:
Sara Radcliffe, President & CEO, California Life Sciences Association (CLSA)
Cartier Esham, Executive Vice President, Emerging Companies, Biotechnology Industry Organization (BIO)
Andy Bressler, Washington Analyst, Bank of America Merrill Lynch

10:15 am Break/Transition - 15 Minutes
10:30 am
PANEL DISCUSSION: Susan G. Komen Foundation - "Patient/Survivor"
Plugging holes in revenue buckets comes with the ABFO member territory.  But at this workshop, hosted by the Susan G. Komen San Diego Foundation, you’ll hear from three breast cancer survivors about how drug discovery helped plug the hole in their life bucket before the sands of time ran out.   Come and hear the patient perspective so key to success in this industry.  Their stories will bring a reality to the work we do. It promises to be a motivating and inspiring session.
  MODERATOR: Bethel Nathan
PANELISTS:

Randi Hosking
Fran Robinson
Rochelle Bradley
12:00 pm
Closing Remarks
12:15 pm
Conference Concludes